According to recent World Health Organization data, approximately 170–200 million people worldwide are infected with hepatitis C virus (HCV). At present, illicit drug users (IDUs) constitute the largest group of individuals infected with HCV in industrial countries. Between 50% and 90% of IDUs are estimated to be positive for anti-HCV antibodies and most of the new infections occur in IDUs. The aim of our review is to focus on tertiary prevention of HCV infection among IDUs. We review strategies to prevent HCV infection and disease progression, attitude to antiviral treatment, access to specific HCV therapy and data of efficacy and safety of antiviral treatment among IDUs.
PerzJ.F., AlterM.J.The coming wave of HCV-related liver disease: dilemmas and challenges.J Hepatol2006; 44: 441–443.
3.
AlterM.J.Epidemiology of hepatitis C virus infection.World J Gastroenterol2007; 13: 2436–2441.
4.
PerzJ.F., ArmstrongG.L., FarringtonL.A., HutinY.J., BellB.P.The contribution of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.J Hepatol2006; 45: 529–538.
5.
FreemanA.J., DoreG.J., LawM.G.Estimating progression to cirrhosis in chronic hepatitis C virus infection.Hepatology2001; 34: 809–816.
6.
Centres for Disease Control and Prevention.Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease.MMWR Recomm Rep1998; 47: 1–39.
7.
KamiliS., KrawcynskiK., McCaustalandK.A., LiX., AlterM.J.The infectivity of hepatitis C virus after drying and storing at room temperature.Infect Control Hosp Epidemiol2007; 28: 519–524.
8.
LapercheS.Blood safety and nucleic acid testing in Europe.Euro Surveill2005; 10: 3–4.
9.
KretzschmarE., ChudyM., NublingC.M., RossR.S., KruseF., TrobishH.First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays.Vox Sang2007; 92: 297–301.
10.
SuttonA.J., GayN.J., EdmundsW.J., HopeV.D., GillO.N., HickmanM.Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.BMC Infect Dis2006; 6: 93.
11.
VillanoS.A., VlahovD., NelsonK.E., LyesC.M., CohnS., ThomasD.L.Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.J Clin Microbiol1997; 35: 3274–3277.
12.
AceijasC., StimsonG.V., HickmanM., RhodesT., United Nations Reference Group on HIV/AIDS Prevention and Care among IDU in Developing and Transitional Countries. Global overview of injecting drug use and HIV infection among injecting drug users.AIDS2004; 18: 2295–2303.
13.
EstebanJ.I., SauledaS., QuerJ.The changing epidemiology of hepatitis C virus infection in Europe.J Hepatol2008; 48: 148–162.
14.
AceijasC., RhodesT.Global estimates of prevalence of HCV infection among injection drug users.Int J Drug Policy2007; 18: 352–358.
15.
ScheinmannR., HaganH., Lelutiu-WeinbergerC.Non injection drug use and hepatitis C virus. A systematic review.Drug Alcohol Depend2007; 89: 1–12.
16.
GalperimB., CheinquerH., SteinA., FonsecaA., LungeV., IkutaN.Prevalence of hepatitis C virus in alcoholic patients: role of parenteral risk factors.Arq Gastroenterol2006; 43: 81–84.
17.
MatheïC., Van DoorenS., LemeyP., Van DammeP., BuntinxF., VandammeA.M.The epidemic history of hepatitis C among injecting drug users in Flanders, Belgium.J Viral Hepat2008; 15: 399–408.
18.
AlterM.J., MoyerL.A.The importance of preventing hepatitis C virus infection among injection drug users in the United States.J Acquir Immune Defic Syndr1998; 18 Suppl 1: S6–S10.
19.
EdlinB.R.Hepatitis C prevention and treatment for substance users in the United states: acknowledging the elephant in the living room.Int J Drug Policy2004; 15: 81–91.
20.
SorensenJ.L., CopelandA.L.Drug abuse treatment as an HIV prevention strategy: a review.Drug Alcohol Depend2000; 59: 17–31.
21.
EllardJ.'There is no profile it is just everyone': the challenge of targeting hepatitis C education and prevention messages to the diversity of current and future injecting drug users.Int J Drug Policy2007; 18: 225–234.
22.
Mateu-GelabertP., TreloarC., CalatayudV.A.How can hepatitis C be prevented in the long term?Int J Drug Policy2007; 18: 338–340.
23.
KamalS.M., FoulyA.E., KamelR.R.Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.Gastroenterology2006; 130: 632–638.
24.
SterlingR.K., SulkowskiM.S.Hepatitis C virus in the setting of HIV or hepatitis B coinfection.Semin Liver Dis2004; 24: 61–68.
25.
VentoS., GarofanoT., RenziniC.Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C.N Engl J Med1998; 338: 286–290.
FosterG.R.Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?Addiction2008; 103: 1412–1413.
28.
EdlinB.R., SealK.H., LorvickJ.Is it justifiable to withhold treatment for hepatitis C from illicit drug users?N Engl J Med2001; 345: 211–214.
29.
DieperinkE., WillenbringM., HoS.B.Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review.Am J Psychiatry2000; 157: 867–876.
30.
KnottA., DieperinkE., WillenbringM.Integrated psychiatric/medical care in chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes.Am J Gastroenterol2006; 101: 2254–2262.
31.
SchaeferM., HinzpeterA., MohmandA.Hepatitis C treatment in “difficult to treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.Hepatology2007; 46: 991–998.
32.
National Institutes of Health.National Institutes of Health Consensus Development Conference Statement: management of hepatitis C.Hepatology2002; 36: S3–S20.
33.
DienstagJ.L., McHutchsonJ.G.American Gastroenterological Association technical review on the management of hepatitis C.Gastroenterology2006; 130: 231–264.
34.
EdlinB.R., CardenM.R.Injection drug users: the overlooked core of the hepatitis C epidemic.Clin Infect Dis2006; 42: 673–676.
35.
CawthorneC.H., RudatK.R., BurtonM.S.Limited success of HCV antiviral therapy in United States veterans.Am J Gastroenterol2002; 97: 149–155.
36.
Falck-YtterY., KaleH., MullenK.D., SarbahS.A., SorescuL., McCulloughA.J.Surprisingly small effect of antiviral treatment in patients with hepatitis C.Ann Intern Med2002; 136: 288–292.
37.
SealK.H., CurrieS.L., ShenH.Hepatitis C treatment candidacy and outcomes among 4318 US Veterans with chronic hepatitis C virus infection. Does a history of injection drug use matter?J Clin Gastroenterol2007; 41: 199–205.
38.
Munoz-PlazaC.E., StraussS., Astone-TwerellJ.Exploring drug users’ attitude and decision regarding hepatitis C (HCV) treatment in the U.S.Int J Drug Policy2008; 19: 71–78.
39.
DoabA., TreloarC., DoreG.J.Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.Clin Infect Dis2005; 40: S313–S320.
40.
RisdahlJ.M., KhannaK.W., PetersonK.W., MolitorT.W.Opiates and infections.J Neuroimmunol1998; 83: 4–18.
41.
NovickD.M., OchshornM., GhaliV.Natural killer cell activity and lymphocyte subset in parenteral heroin abusers and long term methadone maintenance patients.J Pharmacol Exp Ther1989; 250: 606–610.
42.
NeriS., BrunoC.M., PulvirentiD.Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug users.Psychopharmacology (Berl)2005; 179: 700–704.
43.
SacerdoteP., FranchiS., GerraG., LecceseV., PeneraiA.E., SomainiL.Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function.Brain Behav Immun2008; 22: 606–613.
44.
BerkS.I., LitwinA.H., ArnstenJ.H., DuE., SolowayI., GourevitchM.N.Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment.Clin Ther2007; 29: 131–138.
45.
SulkowskiM., WrightT., RossiS.Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy.Clin Pharmacol Ther2005; 77: 214–224.
46.
GuptaS.K., SellersE., SamozaE., AnglesL., KolzK., CulterD.L.The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy.J Clin Pharmacol2007; 47: 604–612.
47.
SylvestreD.L.Treating hepatitis C in methadone maintenance patients: an interim analysis.Drug Alcohol Depend2002; 67: 117–123.
48.
MaussS., BergerF., GoelzJ., JacobB., SchmutzG.A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.Hepatology2004; 40: 120–124.
49.
JeffreyG.P., MacQuillanG., ChuaF.Successful hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants.57th American Association for the Study of Liver Diseases. 27–31 October 2006, Boston, MA, USA. Abstract 375.
50.
SimonovaM., KatzarovK., TakovD.Therapeutic efficacy of 24 weeks’ antiviral treatment in addicted patients on methadone maintenance therapy who have chronic hepatitis C, genotype 1, with low baseline viremia.57th American Association for the Study of Liver Diseases. 27–31 October 2006, Boston, MA, USA. Abstract 363.
51.
BelforiB., ChioderaA., CiliegiP.Treatment of hepatitis C virus in injection drug users on opioid replacement therapy: a prospective multicentre study.Eur J Gastroenterol Hepatol2007; 19: 731–732.
52.
CiaccioA., FerraroD., AlaimoG., MaggioA.M., CraxìA., AlmasioP.Feasibility of combination therapy for chronic hepatitis C in IVDU in the framework of an heroin detoxification protocol.58th American Association for the Study of Liver Diseases. 2–6 November 2007, Boston, MA, USA. Abstract 346.
53.
GuadagninoV., TrottaM.P., MontesanoF.Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programs.Addiction2007; 102: 423–431.
54.
KrookA.L., StokkaD., HegerB., NygaardE.Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.Eur Addict Res2007; 13: 216–221.
55.
NeriS., TravaliS., BertinoG.Immune response in addicts with chronic hepatitis C treated with interferon and ribavirin.J Gastroenterol Hepatol2007; 22: 74–79.
56.
SchaeferM., HinzpeterA., MohmandA.Hepatitis C treatment in ‘difficult to treat’ psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.Hepatology2007; 46: 991–998.
57.
WilkinsonM., CrawfordV., TippetA.Community based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite on-going drug use (HCV drug users).Aliment Pharmacol Ther2008. In press.
58.
ChainuvatiS., KhalidS.K., KancirS.Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.J Viral Hepat2006; 13: 235–241.
59.
BruggmannP., FalcatoL.M., HelblingB.Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients.J Viral Hepat2008; 15: 747–752.
60.
MannsM.P., McHuthisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.Lancet2001; 358: 958–965.
61.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med2002; 347: 975–982.
62.
PoynardT., McHutchisonJ., GoodmanZ., LingM.H., AlbrechtJ.Is an ‘à la carte’ combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?Hepatology2000; 31: 211–218.
63.
DavisG.L., WongJ.B., McHutchisonJ.G., MannsM.P., HarveyJ., AlbrechtJ.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.Hepatology2003; 38: 645–652.
64.
HueppeD., ZehnterE., MannsM.P., MaussS., PrinzingR.Treatment of peginterferon alfa 2b and ribavirin of chronic hepatitis C patients on substitution therapy and outcome in the clinical setting in Germany.57th American Association for the Study of Liver Diseases. 27–31 October 2006, Boston, USA. Abstract 394.
65.
HussainiH., ColeE., FlynnA., BerginJ.Substitute opiate use in intravenous drug users (IVDUs) does not adversely affect sustained virological response (SVR) following treatment of chronic hepatitis C (CHC) with pegylated interferon alpha (PEG-IFN) and ribavirin.57th American Association for the Study of Liver Diseases. 27–31 October 2006, Boston, MA, USA. Abstract 396.
66.
AnagnostouO., ManolakopoulosS., DeutschM.Drug users with chronic hepatitis C who are adherent to antiviral treatment will finally benefit from therapy.Digestive Disease Week. 17–22 May 2008, San Francisco, CA, USA. Abstract S1013.
67.
SchaeferM., SchmidtF., FolwacznyC.Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk group.Hepatology2003; 37: 443–451.
68.
BrigadaR., BonassoM., BorroniG.Overcoming barriers to treatment of hepatitis C in Italian drug users. The importance of a co-management model of care.57th American Association for the Study of Liver Diseases. 27–31 October 2006, Boston, MA, USA. Abstract 374.
69.
GrebelyJ., RaffaJ.D., MeagherC.Directly observed therapy for the treatment of hepatitis C virus infection in current and former drug users.J Gastroenterol Hepatol2007; 22: 1519–1525.
70.
GrebelyJ., GenowayK., KharaM.Treatment uptake and outcome among current and former injection drug users receiving directly observed therapy within multidisciplinary group model for the treatment of hepatitis C virus infection.Int J Drug Policy2007; 18: 437–443.
71.
Van ThielD.H., AnantharajuA., CreechS.Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse.Am J Gastroenterol2003; 98: 2281–2288.
72.
RobaeysG., Van VlierbergheH., MatheïC.. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes.Eur J Gastroenterol Hepatol2006; 18: 159–166.
73.
HuckansM.S., LoftisJ.M., BlackwellA.D., LinkeA., HauserP.Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.Subst Abuse Treat Prev Policy2007; 2: 4.
74.
MaussS., HüppeD., ZehnterE.Opioid maintenance therapy is not associated with treatment failure to hepatitis C therapy in a large German multicentre cohort.58th American Association for the Study of Liver Diseases. 2–6 November 2007, Boston, MA, USA. Abstract 253.
75.
BackmundM., MeyerK., Von ZielonkaK., EichenlaubD.Treatment of hepatitis C infection in injection drug users.Hepatology2001; 34: 188–193.
76.
HuberM., WeberR., OpplingerR.Interferon alpha-2a plus ribavirin 1000/1200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment. An open-label randomized multicenter trial.Infection2005; 33: 25–29.
77.
AntonucciG., LongoM.A., AngelettiC.The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.Am J Gastroenterol2007; 102: 1383–1391.
78.
ThomsonB.J., KwongG., RatibS.Response rate to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management.J Viral Hepat2008; 15: 271–278.
79.
FriedmanE., AyeL., RamirezF.C., GerkinR., TharalsonE., GilaniN.Factors associated with premature discontinuation of chronic hepatitis C virus treatment using pegylated interferon and ribavirin: a four year experience.Digestive Disease Week. 17–22 May 2008, San Francisco, CA, USA. Abstract S1017.
80.
AndriulliA., MangiaA., IacobellisA., IppolitoA., LeandroG., ZeuzemS.Meta-analysis: the outcome of antiviral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.Aliment Pharmacol Ther2008; 28: 397–404.
81.
YuM.L., DaiC.Y., HuangJ.F.Rapid virologic response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Hepatology2008; 47: 1884–1893.
82.
MatthewsA.M., FiremanM., ZuckerB., SobelM., HauserP.Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin.Am J Psychiatry2006; 163: 1342–1347.
83.
NickelT., SonntagA., BackmundM., PollmächerT.Depression during therapy with interferon alpha – how long should an antidepressant treatment last?Pharmacopsichiatry2005; 38: 102–104.
84.
CurrieS.L., RyanJ.C., TracyD.A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus.Drug Alcohol Depend2008; 93: 148–154.
85.
FarciP., AlterH.J., GovindarajanS.Lack of protective immunity against reinfection with hepatitis C virus.Science1992; 258: 135–140.
86.
WhiteP.A., GrebelyJ., FlynnJ.K.Natural history of HCV superinfection and reinfection.59th American Associationfor the Study of Liver Diseases. 31 October–4 November 2008, San Francisco, CA, USA. Abstract 1057.
87.
MicallefJ.M., MacdonaldV., JaunceyM.High incidence of hepatitis C virus reinfection within a cohort of injecting drug users.J Viral Hepat2007; 14: 413–418.
88.
GrebelyJ., ConwayB., RaffaJ.D., LaiC., KrajdenM., TyndallM.W.Hepatitis C virus reinfection in injection drug users.Hepatology2006; 44: 1139–1145.
89.
EdlinB.R.Prevention and treatment of hepatitis C in injection drug users.Hepatology2002; 36: S210–S19.
90.
SchaeferM., HeinzA., BackmundM.Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?Addiction2004; 99: 1167–1175.
91.
NovickD.M., KreekM.J.Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.Addiction2008; 103: 905–918.
92.
MuirA.J., ProvenzaleD.A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection.J Clin Gastroenterol2002; 34: 268–271.
93.
YawnB.P., WollanP., GazzuolaL.Diagnosis and 10-year follow-up of a community-based hepatitis C cohort.J Fam Pract2002; 51: 135–140.
94.
Gazzuola RoccaL., YawnB.P., WollanP., KimW.R.Management of patients with hepatitis C in a community population: diagnosis, discussion and decision to treat.Ann Fam Med2004; 2: 116–124.
95.
ButtA.A., WagenerM., ShakilA.O., AhmadJ.Reasons for no-treatment of hepatitis C in veterans in care.J Viral Hepat2005; 12: 81–85.
96.
BiniE.J., BräuN., CurrieS.Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. Veterans with chronic hepatitis C virus infection.Am J Gastroenterol2005; 100: 1772–1779.
97.
MorrillJ.A., ShresthaM., GrantR.W.Barriers to the treatment of hepatitis C.J Gen Intern Med2005; 20: 754–758.
98.
CheungR.C., CunninghamB.A., CooperA.D.Effectiveness of screening program for hepatitis C.Dig Dis Sci2006; 51: 976–981.
99.
EvonD.M., VermaA., DoughertyK.High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities.Dig Dis Sci2007; 52: 3251–3258.
100.
JowettS.L., AgarwallK., SmithB.C.Managing chronic hepatitis C acquired through intravenous drug use.QJM2001; 94: 153–158.
101.
CournotM., GlibertA., CastelF.Management of hepatitis C in active drug users: experience of an addiction care hepatology unit.Gastroenterol Clin Biol2004; 28: 533–539.
102.
DalgardO.Follow-up studies of treatment for hepatitis C virus infection among injection drug users.Clin Infect Dis2005; 40: S336–S338.
103.
GrebelyJ., RaffaJ.D., GenowayK.Infrequent hepatitis C virus (HCV) re-infection after sustained virological response (SVR) among current and former drug users (IDUS) having received treatment of HCV infection.58th American Association for the Study of Liver Diseases. 2–6 November 2007, Boston, MA, USA. Abstract 295.
